Tenascin-C: Exploitation and collateral damage in cancer management - Wikidata - awgldk - TriplyDB

Tenascin-C: Exploitation and collateral damage in cancer management

Tenascin-C: Exploitation and collateral damage in cancer management

http://www.wikidata.org/entity/Q35577959

about

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations.Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation.Tenascin-C serum levels and its prognostic power in non-small cell lung cancer.Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling.Shear force-based genetic screen reveals negative regulators of cell adhesion and protrusive activity.Regulation of cellular redox signaling by matricellular proteins in vascular biology, immunology, and cancer Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival.Tenascin-C promotes migration of hepatic stellate cells and production of type I collagen.Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity.

P2860

Q35955393-03EE9557-FA32-4697-A472-187A3B9D9249 Q36245163-F99FA64C-CC81-4C7D-A62D-CD0109C8D2A9 Q36705901-6DFBB36B-1996-444C-B9C3-AEE7EE91F2B2 Q37190491-BE469EC2-3FB0-4293-9793-72D8E608DA25 Q37228242-FCDF31A1-DFB9-40C6-A92B-299D9FF98337 Q38605157-7ED62120-4FC3-47BD-BC74-49C8FD7FFA42 Q38656989-6EEBF4D6-1027-430A-AD22-BA382C6F5669 Q38708023-49766CC5-66FA-4B7F-B019-8B9F7F714E88 Q39875332-FF1C86E4-1CD2-4280-90A4-A5B5189B3C2E Q49553693-781F6BAE-293B-4F2D-83D0-524CEEB0FC41

P2860

Tenascin-C: Exploitation and collateral damage in cancer management

http://www.wikidata.org/entity/Q35577959

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tenascin-C: Exploitation and collateral damage in cancer management

@ast

Tenascin-C: Exploitation and collateral damage in cancer management

@en

type

label

Tenascin-C: Exploitation and collateral damage in cancer management

@ast

Tenascin-C: Exploitation and collateral damage in cancer management

@en

prefLabel

Tenascin-C: Exploitation and collateral damage in cancer management

@ast

Tenascin-C: Exploitation and collateral damage in cancer management

@en

P1433

Q35577959-301BB55D-E658-4280-867B-5C9BC6CBC6CB

P1476

Q35577959-3B1240D5-88BE-4F66-8A32-A75D6A4A4CF3

P2093

Q35577959-153071F5-85A1-486E-B30E-6EECEDD08D79

Q35577959-2D87ABE3-AEC5-4A69-97D4-9EA874FE1D3C

Q35577959-4896A2E2-DB05-4D73-ADD8-A09371BD7CE5

Q35577959-9850CCED-2A49-4253-9D49-937F08518857

P275

Q35577959-CC57EF78-2292-471F-9BF5-C1CF1424B56D

P2860

Q35577959-0217771E-F596-41A0-89FE-333FC616B6BB

Q35577959-03DC6EA8-76DF-4C71-BA4D-B74C73EA863B

Q35577959-0532439A-8D32-41BC-95B2-06113D367D92

Q35577959-07CA84C7-E976-4675-B4F4-429A08D7BD01

Q35577959-08C00DFD-F0F0-4B4E-BEFE-040C24CCB248

Q35577959-0B073C95-243B-4E2E-B302-1681B4DA735E

Q35577959-0F728810-F9DC-46D1-AB0D-2351DB5CBA16

Q35577959-0FAA85B2-6235-4D0A-B32F-DEB6574C356A

Q35577959-14141C5B-979B-4EA8-89D7-88827841527C

Q35577959-1680C4AB-FB3F-41C3-818F-010329C8CD1D

P304

Q35577959-1EBD3C04-59F9-4346-9D52-7BDCCBEEE26C

P31

Q35577959-35A6EF20-A546-4367-AFE5-5E3B8DB83F4F

Q35577959-8926C085-B2B4-464A-BDD8-7575DB7871EC

P356

Q35577959-4DE06FF5-B140-4911-9E73-6D9A11EB9B3A

P433

Q35577959-CB61CB3E-328D-449A-AB6D-7B587DCF11FF

P478

Q35577959-6F55B6C4-3BCD-4099-84BE-74EB70F207CD

P50

Q35577959-475FE14D-8798-4B41-B061-D2D88227E25D

Q35577959-D2969C43-4C22-45D9-B21F-BA1AF4C2ED4F

P5008

Q35577959-C7B174D6-96DC-4BC1-89C4-CF5AFB2DE370

P577

Q35577959-97DD04CB-8100-4282-859A-5F47D4E0F98F

P5875

Q35577959-96BB438B-99CC-46B7-9D05-A7AEBF026417

P698

Q35577959-97AD77CB-FEA3-4D84-9572-0E50228BD487

P921

Q35577959-312526DB-0FA7-4627-A206-CBCBA1DA64EC

Q35577959-EB2CE460-81AB-448D-B92A-F11215B17B2E

Q35577959-FD712C61-8B80-4773-B041-AFC1A466658B

P932

Q35577959-6146DAF3-B999-40D7-8D6F-760BE0DB00BC

P356

19336918.2014.1000074

P1433

Cell Adhesion and Migration

P1476

Tenascin-C: Exploitation and collateral damage in cancer management

@en

P2093

Falk Saupe

http://www.w3.org/2001/XMLSchema#string

Gertraud Orend

http://www.w3.org/2001/XMLSchema#string

Hélène Burckel

http://www.w3.org/2001/XMLSchema#string

Kim Midwood

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 3.0 Unported

P2860

Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment

Second malignant neoplasms and cardiovascular disease following radiotherapy.

A systems biology view of blood vessel growth and remodelling

Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA

Tenascin-C induced signaling in cancer

Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1

Expression and distribution of tenascin in rat submandibular glands following irradiation.

Fitting the linear-quadratic model to detailed data sets for different dose ranges.

P304

141-153

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/19336918.2014.1000074

http://www.w3.org/2001/XMLSchema#string

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Caroline Spenlé

P5008

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270661013

http://www.w3.org/2001/XMLSchema#string

P698

25569113

http://www.w3.org/2001/XMLSchema#string

P921

fibrous protein

P932

4422814

http://www.w3.org/2001/XMLSchema#string